VJHemOnc is committed to improving our service to you

EHA 2020 | Evaluating CPX-351 against 7+3 in older newly diagnosed AML

VJHemOnc is committed to improving our service to you

Jeffrey Lancet

Jeffrey Lancet, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, outlines the five-year final results of a Phase III study evaluating CPX-351, a liposomal preparation of cytarabine and daunorubicin at a synergistic ratio, against 7+3 in older, newly diagnosed acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter